SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.800
-0.070 (-1.81%)
Jun 26, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 11.6, with a low estimate of 6.00 and a high estimate of 16. The average target predicts an increase of 205.26% from the current stock price of 3.80.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $13 | Buy | Initiates | $13 | +242.11% | Jun 24, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 → $16 | Buy | Reiterates | $14 → $16 | +321.05% | Jun 17, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $6 | Buy | Maintains | $6 | +57.89% | Jun 16, 2026 |
| Citi | Citi | Buy Reiterates $11 | Buy | Reiterates | $11 | +189.47% | Jun 16, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +268.42% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
62.50K
EPS This Year
-1.28
from -0.81
EPS Next Year
-0.98
from -1.28
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 500,000 | |
| Avg | n/a | 62,500 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 63,580.0% |
| Avg | - | 13,370.8% |
| Low | - | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.06 | -0.54 | |
| Avg | -1.28 | -0.98 | |
| Low | -1.88 | -1.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.